References
- O’Bryan TA. Pseudallescheriasis in the 21st century. Expert Rev Anti Infect Ther 2005; 3(5): 765–773
- Jayamohan Y, Ribes JA. Pseudallescheriasis: a summary of patients from 1980-2003 in a tertiary center. Arch Pathol Lab Med 2006; 130(12): 1843–1846
- Meyer RD, Gaultier CR, Yamashita JT, Babapour R, Ntchon HE, Wolfe PR. Fungal sinusitis in patients with AIDS: report of 4 cases and review of Rerature. Medicine (Baltimore) 1994; 73(2): 69–78
- Horton CK, Huang L, Goozé. Pseudallescheria boydii infection in AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20(2): 209–211
- Sateesh CS, Makannavar JH. Chronic sino-naso-orbtl fungal infection due to Pseudallescheria boydii in a nonim-munocompromised host — a case report. Indian J Pathol Microbiol 2001; 44(3): 359–361
- Baradkar VP, Mathur M, Kumar S. Invasive fungal sinusitis resulting in orbital apex syndrome in a HIV positive patient. Indian J Pathol Microbiol 2010; 53(1): 185–187
- Troke P, Aguirrebengoa K, Artega C, et al., on behalf of the Global Scedospodum Study Group. Treatment of Scedosporiosis with voriconazole: Clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52(5): 1743–1750
- Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedopodum. Clin Microbiol Rev 2008; 21(1):1 57-1 97
- Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scediosporum proliferans in transplant recipients: clinical characteristics and impact of antifungal therapy on outcome. Clin Infect Dis 2005; 40(1): 89–99
- Liu P, Foster G, Gandelman K. Steady state pharmacokinetic and safety profiles of voriconazole and rtonavir in healthy male subjects. Antimicrob Agents Chemother 2007; 51(10): 3617–326
- Gilgado, F, Cano, J., Gen, J., Sutton, D.A., Guarro, J. Molecular and Phenotypic Data Supporting Distinct Species Statuses for Scedosporium apiospermum and Pseudallescheria boydii and the Proposed New Species Scedospodum dehoogii. J Clin Microbiol 2008; 46: 766–771